- Home
- MKZR vs GOVX Comparison
MKZR vs GOVX Comparison
Compare MKZR & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MKZR | GOVX |
|---|---|---|
| Founded | 2012 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 3.0M |
| IPO Year | 2012 | 1996 |
Fundamental Metrics
Financial Performance| Metric | MKZR | GOVX |
|---|---|---|
| Price | $1.38 | $0.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 6.8K | ★ 236.6K |
| Earning Date | 09-28-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.87 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $20,007,414.00 | $2,489,145.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.83 | $0.12 |
| 52 Week High | $6.00 | $4.40 |
Technical Indicators
Market Signals| Indicator | MKZR | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 46.44 | 33.65 |
| Support Level | $1.37 | $0.16 |
| Resistance Level | $1.84 | $0.86 |
| Average True Range (ATR) | 0.06 | 0.03 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 34.78 | 36.37 |
Price Performance
Historical ComparisonAbout MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate. It is a real estate investment manager who utilizes an approach to real estate securities, often seeing opportunities that others overlook. Based in Orinda, California, MacKenzie Capital Management has specialized in discounted real estate securities and asset management.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.